With interest we read the paper by Juste et al 1 proposing the amount of zymogen-granule membrane glycoprotein 2 (GP2) on the surface of intestinal bacteria as a Crohn's disease (CD) marker. Indeed, a decreased GP2 level was found on microbes in patients with CD as compared to those of healthy controls. GP2 is a homologue to the urinary Tamm-Horsefall protein demonstrating an antimicrobial function by binding type 1-fimbriated uropathogenic Escherichia coli (UPEC). Likewise, GP2 seems to interact with intestinal bacteria as a specific receptor of bacterial type-1 fimbriae (FimH) on intestinal microfold cells that are partaking in immune responses against such microbes.2 GP2 is overexpressed in the inflamed intestine of patients with CD and has an immunomodulating role in innate and acquired immune responses.3 ,4Interestingly, GP2 was identified as autoantigen of pancreatic antibodies in CD.4 Altogether, these findings indicate two major GP2 sources (pancreatic/intestinal) and support a role for GP2 in the interaction between the immune system and intestinal microbiota.3 Thus, loss of tolerance to GP2 could play a role in CD's pathophysiology supposed to be exacerbated by preceding intestinal infections. In general, the findings by Juste et al 1 may be explained by a lower pancreatic GP2 secretion, an impaired GP2 binding to bacteria, or by a higher prevalence of bacteria with poor or no GP2 binding in patients with CD.
response before measuring any drug or antidrug antibody levels. Without the correct context of loss of response, interpretation of drug and antidrug antibody levels would be inappropriate, especially so when drug levels are found to be of therapeutic levels. When properly defined, customised treatment based on therapeutic drug monitoring will avoid unhelpful dose-intensification of biologics for some patients and be cost-efficient from a macro-economic level.
Nevertheless, I would like to congratulate the authors for undertaking the task of demonstrating the cost effectiveness of individualised biologic therapy for patients with complicated CD in the era of personalised medicine.
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Species-specific and pathotype-specific binding of bacteria to zymogen granule membrane glycoprotein 2 (GP2) Dear Editor, With interest we read the paper by Juste et al 1 proposing the amount of zymogen-granule membrane glycoprotein 2 (GP2) on the surface of intestinal bacteria as a Crohn's disease (CD) marker. Indeed, a decreased GP2 level was found on microbes in patients with CD as compared to those of healthy controls. GP2 is a homologue to the urinary Tamm-Horsefall protein demonstrating an antimicrobial function by binding type 1-fimbriated uropathogenic Escherichia coli (UPEC). Likewise, GP2 seems to interact with intestinal bacteria as a specific receptor of bacterial type-1 fimbriae (FimH) on intestinal microfold cells that are partaking in immune responses against such microbes. 2 GP2 is overexpressed in the inflamed intestine of patients with CD and has an immunomodulating role in innate and acquired immune responses. 3 4 Interestingly, GP2 was identified as autoantigen of pancreatic antibodies in CD. 4 Altogether, these findings indicate two major GP2 sources ( pancreatic/intestinal) and support a role for GP2 in the interaction between the immune system and intestinal microbiota. 3 Thus, loss of Figure 1 Binding of Escherichia coli pathotypes to GP2. Human recombinant GP2 expressed in Sf9 cells were immobilised on 96-well plates with anti-FimH antibodies used as positive, or human serum albumin as negative controls. After incubation of bacterial suspensions for 2 h followed by subsequent washing, bound bacteria were stained with a fluorescent dye and counted with an automated fluorescence interpretation system (Aklides, Medipan, Dahlewitz, Germany tolerance to GP2 could play a role in CD's pathophysiology supposed to be exacerbated by preceding intestinal infections. In general, the findings by Juste et al 1 may be explained by a lower pancreatic GP2 secretion, an impaired GP2 binding to bacteria, or by a higher prevalence of bacteria with poor or no GP2 binding in patients with CD.
We have a longstanding interest in GP2's intestinal function and, therefore, we evaluated GP2 as receptor for intestinal bacterial pathotypes by testing the binding of 284 bacteria in a novel binding assay. 5 Nine out of 10 fimH-negative isolates showed low binding to GP2, and one HFEC isolate a high binding rate (473 bpi). GP2 binding of Salmonella, E. coli and other bacterial groups was mannose-sensitive and not glucosesensitive as shown by inhibition experiments proving a GP2-FimH interaction.
To investigate the interaction between FimH-protein and GP2 at a molecular level, we sequenced fimH genes of 48 E. coli isolates: six isolates of each pathotype including two isolates not binding to GP2, two isolates showing medium and two isolates showing strong binding. Thus, we defined 23 different FimHamino acid sequences. Though there was no specific FimH-amino acid sequence variation for an E. coli pathotype, FimH sequences seem to correlate with the strength of binding of GP2 to bacteria (figure 2). Additionally, bacterial binding to GP2 correlated significantly with that to anti-FimH antibodies, indicating that FimH-expression levels are associated with GP2 binding ( p<0.0001, see online supplementary data).
We conclude that GP2 is an intestinal epithelial receptor interacting with distinct FimH-positive bacteria. This interaction can be modulated by pancreatic GP2 secreted together with zymogens into the intestine. GP2 binding is selective for bacterial species and pathotypes and, thus, may determine immune responses to the intestinal microbiota. CAEC do not differ in their binding from most E. coli isolates supporting the assumptions that other bacteria with low GP2 binding are more abundant in CD, or the GP2 interaction with CAEC is impaired.
The effect of exercise and diet on gut microbial diversity
We have read with great interest the study by Clarke et al 1 who in a very elegant and sophisticated manner documented the increase in gut microbial diversity in association with exercise and dietary extremes in professional rugby players. The observed microbial shifts were accompanied by lower inflammatory and healthier metabolic profiles among athletes. Significantly higher proportions of the genus Akkermansia muciniphila in athletes as well as in low Body Mass Index control group were found. As previously shown, the presence of these bacteria in the human GI tract has been associated with improved metabolic profiles, possibly due to enhanced barrier function. However, from the study of Clarke et al it is difficult to draw the conclusion and assess the impact of exercise per se from dietary influences in groups studied for their gut microbial diversity. As the alterations of the microbial diversity have already been linked to changes in dietary habits, it is important to address an important issue, which is the reported high prevalence of GI presentations among professional athletes. Endurance training has been associated with reduced GI blood flow, tissue hyperthermia and hypoxia leading to possible alterations of microbiota and GI barrier. As documented in a well-designed and randomised, double-blinded, placebo-controlled trial, probiotic supplementation affected markers of intestinal barrier, oxidation and inflammation in trained men. Lamprecht et al have shown that a 14-week period of supplementation with multi-species probiotics in trained men led to normalisation of stool zonulin concentrations (a marker indicating enhanced gut permeability) as compared with the placebo group. The researchers found no effect of exercise on tumour necrosis factor-α serum concentrations. 2 Other studies with high endurance athletes documented beneficial effects of dietary interventions on improvements in cytokines and immune-marker panels, positive effects on redox biology and lessening of GI symptoms. As implicated in the study by Clarke et al, the gut microbial diversity may be viewed as a new biomarker or indicator of health. However, Wills et al 3 in their recent prospective study using next-generation sequencing for examining the faecal microbiota composition in patients with IBD during a quiescent disease phase and a subsequent exacerbation could not demonstrate general changes in microbial composition or diversity in both groups studied. Of importance, a large increase in relative abundance of Bacteroides fragilis or Akkermansia muciniphila during active phase of disease in some of patients was reported. 3 Other studies document that prolonged strenuous exercise expands the population of developmentally early stem cells in bone marrow and mobilises them into peripheral blood (personal communication, Dr Ratajczak, University of Lousiville, USA). 4 The precise mechanism of this phenomenon is not known; however, it could play an important role in tissue/organ rejuvenation after strenuous exercise. Our group has documented an increase in mobilisation of stem and progenitor cells into peripheral blood in patients with active IBD. 5 It is difficult to exclude that these health effects are at least in part mediated by gut derived bacterial lipopolysaccharides (endotoxins), which enter the general circulation due to impaired gut barrier integrity and increased intestinal permeability-factors which could be considered more important health determinants than microbial composition itself. It would be very tempting to address the role of intestinal barrier (eg, by measuring intestinal markers such as intestinal-fatty acid binding protein or zonulin) or to measure the levels of serum endotoxin in future studies investigating the effect of exercise and diet on gut microbiota. Observations that antibiotic treatment abolishes stem/progenitor cell mobilisation
